- Home
- Mutual Funds
- Nippon India Mutual Fund
- Nippon India Pharma Fund-growth
Fund Overview of Nippon India Pharma Fund-growth
-
₹8,635.7 CrAUM
-
₹535.25NAV
-
1.78%Expense Ratio
-
EquityFund Category
Minimum amount you can invest: ₹500
Maximum amount you can invest: ₹1,00,000
We have used a return rate of 15% for our calculations.
Returns of Nippon India Pharma Fund-growth
| Tenure | Absolute(%) | Annualised(%) | Category Average(%) |
|---|---|---|---|
| 3 Months | 7.01% | NA | 6.12% |
| 6 Months | 5.57% | NA | 12.92% |
| 1 Year | 5.52% | 5.52% | 6.04% |
| 2 Years | 18.21% | 8.72% | 24.93% |
| 3 Years | 74.66% | 20.43% | 25.71% |
| 5 Years | 81.33% | 12.64% | 19.91% |
| 7 Years | 284.38% | 21.21% | NA |
| 10 Years | 311.95% | 15.21% | 12.78% |
Compare Nippon India Pharma Fund-growth with other mutual funds in the same category
Nippon India Pharma Fund-growth
SBI Healthcare Opportunities Fund Direct Plan-growth
SBI Healthcare Opportunities Fund Direct Plan-idcw
Asset Allocation
equities
97.98%debt instruments
0.00%other assets or cash equivalents
2.02%Nippon India Pharma Fund-growth is one Equity mutual fund offered by Nippon India Mutual Fund. Launched on 05 Jun 2004, the fund aims Long term capital growth. Investment in equity and equity related Securities of pharma & other associated companies. It manages assets worth ₹8,635.7 crore as on Sun May 31, 2026. The expense ratio stands at 1.78%. Fund Manager Manager EducationAbout Nippon India Pharma Fund-growth
The portfolio allocation consists of 97.98% in equities, 0.00% in debt instruments, 2.02% in other assets or cash equivalents.Managed by Sailesh Raj Bhan, it has delivered a return of 5.52% in the last year, a total return since inception of 19.79%.
People planning wealth creation frequently compare the best sip plan in order to plan sustainable wealth.
Key Metrics of Nippon India Pharma Fund-growth
-
Standard Deviation15.78%
-
Sharpe Ratio1.00%
-
Alpha-1.33%
-
Beta0.90%
Fund Details
|
|
Top Performing Mutual Funds
| Fund Names | AUM (Cr) | 1M | 3M | 1Yr | 3Yr | 5Yr |
|---|---|---|---|---|---|---|
SBI Healthcare Opportunities Fund Direct Plan-growth  |
₹4,566 | 1.67% | 13.30% | 10.49% | 24.74% | 16.80% |
| SBI Healthcare Opportunities Fund Direct Plan-idcw |
₹4,566 | 1.67% | 13.30% | 10.49% | 24.74% | 16.80% |
ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-growth  |
₹6,454 | -1.21% | 11.20% | 7.32% | 26.34% | 16.48% |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-idcw |
₹6,454 | -1.21% | 11.20% | 7.32% | 26.34% | 16.48% |
| Mirae Asset Healthcare Fund Direct-growth |
₹3,091 | -0.79% | 9.54% | 13.22% | 24.88% | 15.73% |
| Mirae Asset Healthcare Fund Direct-idcw |
₹3,091 | -0.79% | 9.54% | 13.22% | 24.88% | 15.73% |
| DSP Healthcare Fund Direct-growth |
₹3,309 | 3.03% | 14.21% | 8.50% | 22.68% | 15.62% |
| DSP Healthcare Fund Direct-idcw |
₹3,309 | 3.03% | 14.21% | 8.50% | 22.68% | 15.62% |
| SBI Healthcare Opportunities Fund-growth |
₹4,566 | 1.58% | 13.02% | 9.38% | 23.45% | 15.57% |
| SBI Healthcare Opportunities Fund-idcw |
₹4,566 | 1.58% | 13.02% | 9.38% | 23.45% | 15.57% |
growth is based on 1-month returns of the funds & Top fund are based on 3Y Returns
More funds from Nippon India Mutual Fund
| Fund Names | AUM (Cr) | 1M | 3M | 6M | 1Yr | 3Yr |
|---|---|---|---|---|---|---|
|
Nippon India Pharma Fund Direct-growth
|
₹8,636 | -1.70% | 7.25% | 6.03% | 6.47% | 21.51% |
|
Nippon India Pharma Fund-idcw
|
₹8,636 | -1.78% | 7.01% | 5.57% | 5.52% | 20.43% |
|
Nippon India Pharma Fund Direct-idcw
|
₹8,636 | -1.70% | 7.25% | 6.03% | 6.47% | 21.51% |
|
Nippon India Nifty Pharma Etf-growth
|
₹1,570 | -1.90% | 6.91% | 7.02% | 12.34% | 22.73% |
growth is based on 1-month returns of the fundsMutual Fund Calculator
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 29
- 31
- 32
- 33
- 34
- 36
- 37
- 38
- 39
- 40
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 30
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 29
- 31
- 32
- 33
- 34
- 36
- 37
- 38
- 39
- 40
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 30
Top Mutual Funds
| Fund Names | AUM (Cr) | NAV | 3Yr | 5Yr | 10Yr |
|---|---|---|---|---|---|
| Nippon India Pharma Fund-growth |
₹8,636 | ₹535.25 | 20.43% | 12.64% | 15.21% |
| Nippon India Pharma Fund Direct-growth |
₹8,636 | ₹601.05 | 21.51% | 13.66% | 16.24% |
| Nippon India Pharma Fund-idcw |
₹8,636 | ₹115.58 | 20.43% | 12.64% | 15.21% |
| Nippon India Pharma Fund Direct-idcw |
₹8,636 | ₹164.49 | 21.51% | 13.66% | 16.24% |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund-growth |
₹6,454 | ₹41.36 | 25.28% | 15.47% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-growth |
₹6,454 | ₹44.89 | 26.34% | 16.48% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund-idcw |
₹6,454 | ₹24.13 | 25.28% | 15.47% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-idcw |
₹6,454 | ₹27.11 | 26.34% | 16.48% | - |
| SBI Healthcare Opportunities Fund-growth |
₹4,566 | ₹468.57 | 23.45% | 15.57% | 13.35% |
| SBI Healthcare Opportunities Fund Direct Plan-growth |
₹4,566 | ₹541.52 | 24.74% | 16.80% | 14.59% |
Detailed Portfolio
| Stocks | Sector | % of Holding | Value |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Healthcare | 13.35% | ₹1,152.63 Cr |
| Lupin Ltd | Healthcare | 7.31% | ₹631.33 Cr |
| Dr. Reddy's Laboratories Ltd | Healthcare | 6.72% | ₹580.02 Cr |
| Cipla Ltd | Healthcare | 6.16% | ₹531.69 Cr |
| Divi's Laboratories Ltd | Healthcare | 5.80% | ₹500.53 Cr |
| Apollo Hospitals Enterprise Ltd | Healthcare | 5.20% | ₹448.72 Cr |
| Mankind Pharma Ltd. | Healthcare | 3.94% | ₹339.99 Cr |
| Medplus Health Services Ltd | Healthcare | 3.68% | ₹317.37 Cr |
| Sai Life Sciences Ltd. | Healthcare | 3.43% | ₹296.47 Cr |
| Ajanta Pharma Ltd | Healthcare | 3.21% | ₹277.17 Cr |
| Vijaya Diagnostic Centre Ltd | Healthcare | 3.21% | ₹277.09 Cr |
| Max Healthcare Institute Ltd | Healthcare | 2.97% | ₹256.53 Cr |
| Thyrocare Technologies Ltd | Healthcare | 2.56% | ₹221.10 Cr |
| Ipca Laboratories Ltd | Healthcare | 2.41% | ₹208.04 Cr |
| Glaxosmithkline Pharmaceuticals Ltd | Healthcare | 2.34% | ₹201.84 Cr |
| Aurobindo Pharma Ltd | Healthcare | 2.32% | ₹200.07 Cr |
| Abbott India Ltd | Healthcare | 2.31% | ₹199.64 Cr |
| Repo | Unspecified | 2.16% | ₹186.42 Cr |
| Gland Pharma Ltd | Healthcare | 2.09% | ₹180.12 Cr |
| Alkem Laboratories Ltd | Healthcare | 2.06% | ₹177.96 Cr |
Top Equity Funds
| Fund Names | NAV | 3Yr | 5Yr | 52 weeks high |
|---|---|---|---|---|
| SBI Healthcare Opportunities Fund Direct Plan-growth |
₹541.52 | 24.74% | 16.80% | - |
| SBI Healthcare Opportunities Fund Direct Plan-idcw |
₹376.23 | 24.74% | 16.80% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-growth |
₹44.89 | 26.34% | 16.48% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-idcw |
₹27.11 | 26.34% | 16.48% | - |
| Mirae Asset Healthcare Fund Direct-growth |
₹47.24 | 24.88% | 15.73% | - |
| Mirae Asset Healthcare Fund Direct-idcw |
₹28.45 | 24.88% | 15.73% | - |
| DSP Healthcare Fund Direct-growth |
₹46.19 | 22.68% | 15.62% | - |
| DSP Healthcare Fund Direct-idcw |
₹26.71 | 22.68% | 15.62% | - |
| SBI Healthcare Opportunities Fund-growth |
₹468.57 | 23.45% | 15.57% | - |
| SBI Healthcare Opportunities Fund-idcw |
₹295.17 | 23.45% | 15.57% | - |
growth is based on 5Y returns of the funds
Frequently Asked Questions
Nippon India Pharma Fund-growth
What is the current AUM of Nippon India Pharma Fund-growth?
As of Sun May 31, 2026, Nippon India Pharma Fund-growth manages assets worth ₹8,635.7 crore
How has Nippon India Pharma Fund-growth performed recently?
- 3 Months: 7.01%
- 6 Months: 5.57%
What is the long-term performance of Nippon India Pharma Fund-growth?
- 3 Years CAGR: 20.43%
- 5 Years CAGR: 12.64%
- Since Inception: 19.79%
What is the portfolio composition of Nippon India Pharma Fund-growth?
Equity: 97.98%, Debt: 0.00%, Others: 2.02%.
Who manages Nippon India Pharma Fund-growth?
Nippon India Pharma Fund-growth is managed by Sailesh Raj Bhan from Nippon India Mutual Fund.
What is the market-cap allocation of Nippon India Pharma Fund-growth?
Large Cap: 41.03%, Mid Cap: 27.91%, Small Cap: 31.06%.
Which are the top companies Nippon India Pharma Fund-growth has invested in?
- Sun Pharmaceutical Industries Ltd – 13.35% of the fund's portfolio
- Lupin Ltd – 7.31% of the fund's portfolio
- Dr. Reddy's Laboratories Ltd – 6.72% of the fund's portfolio
- Cipla Ltd – 6.16% of the fund's portfolio
- Divi's Laboratories Ltd – 5.80% of the fund's portfolio
Which are the major sectors Nippon India Pharma Fund-growth focuses on?
- Healthcare – 81.07% of the fund's portfolio
- Unspecified – 2.16% of the fund's portfolio
Policybazaar does not endorse rates/returns or recommend any particular insurer, fund house, AMC (Asset Management Company), insurance and mutual fund product.
Please consult your financial advisor for an informed decision.
Past performance may not be indicative of future results.
The information presented on this page is not owned or generated by Policybazaar. The data has been collected from publicly available sources and online research. We do not claim any ownership or guarantee the accuracy, completeness, or timeliness of this information. It is shared solely for the informational purpose of the viewer and should not be considered as financial advice.
Policybazaar is not acting as a financial advisor, broker, or agent for any mutual fund mentioned here.
Mutual fund investments are subject to market risks. Please read all scheme-related documents carefully before investing.
Policybazaar shall not be held responsible or liable for any losses, damages, or decisions made based on the information provided on this page.
For a complete list of mutual funds registered in India, please refer to the Securities and Exchange Board of India (SEBI) website at www.sebi.gov.in. We do not sell, endorse, or recommend any mutual fund or investment product. For a complete list of mutual funds registered in India, please refer to the Securities and Exchange Board of India (SEBI) website at www.sebi.gov.in. We do not sell, endorse, or recommend any mutual fund or investment product.
For more details on risk factors, terms, and conditions, please read the sales brochure and benefit illustration carefully before concluding a sale.
Policybazaar is a registered Insurance Broker | Registration No. 742, Registration Code No. IRDA/ DB 797/ 19, Valid till 09/06/2024, License category- Direct Broker (Life & General) |CIN: U74999HR2014PTC053454 | Registered Office - Plot No.119, Sector - 44, Gurgaon, Haryana – 122001 |Visitors are hereby informed that their information submitted on the website may be shared with insurers. Product information is authentic and solely based on the information received from the insurers.©️ Copyright 2008-2025 policybazaar.com. All Rights Reserved
^Returns as on 10th Jan’25. Tata AIA Life Top 200 ULIP Fund has delivered 18% returns over the last 10 years. Past performance is not necessarily indicative of future results. This disclaimer is specifically regarding a ULIP fund and is not related to mutual funds. Source: Morningstar.
